Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.

Abstract:

:Calcineurin inhibitor (CNI)-sparing T-cell depleted (TCD) hematopoietic stem cell transplants (HSCTs) are presumed to be less nephrotoxic than conventional HSCTs. We evaluated incidence and risk factors for kidney failure and chronic kidney disease (CKD) in 231 TCD and 212 conventional HSCT recipients. Kidney failure required a median glomerular filtration rate (GFR) <60 ml/min/1.73 m2 for ⩾100 days anytime after 180-days post-HSCT. Two-year cumulative incidence (CI) of kidney failure was 42% in the conventional versus 31% in the TCD group (P=0.005). TCD, age, acute kidney injury and number of toxic CNI levels all impacted on kidney failure, which was associated with increased all-cause mortality (hazard ratio 2.86 (95% CI: 1.88-4.36), P<0.001). Renal recovery occurred in 28% of kidney failure patients whereas the remaining patients were defined to have CKD. In those with baseline GFR>60 ml/min/1.73 m2, only exposure to nephrotoxic medications was associated with CKD (P=0.033). In the myeloablative-conditioning subgroup only total body irradiation was associated with CKD (P=0.013). Of all patients, five (1.13%) required dialysis. These results confirm an impact of TCD on kidney failure but not CKD for which other risk factors such as radiation or nephrotoxic drug exposure may have a role.

journal_name

Bone Marrow Transplant

authors

Glezerman IG,Devlin S,Maloy M,Bui M,Jaimes EA,Giralt SA,Jakubowski AA

doi

10.1038/bmt.2016.343

subject

Has Abstract

pub_date

2017-05-01 00:00:00

pages

733-738

issue

5

eissn

0268-3369

issn

1476-5365

pii

bmt2016343

journal_volume

52

pub_type

杂志文章
  • Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.

    abstract::Six patients treated for relapsed chronic myeloid leukaemia after allogeneic bone marrow transplantation with donor buffy coat transfusions were investigated. In the 5 patients who achieved molecular remission high frequencies of host-reactive interleukin 2-secreting T helper cell precursors (Th-p) were detectable by ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bunjes D,Theobald M,Hertenstein B,Wiesneth M,Novotny J,Arnold R,Heimpel H

    更新日期:1995-05-01 00:00:00

  • High dose therapy and autologous bone marrow transplant (ABMT) in acute leukemia: is purging necessary?

    abstract::Multiple clinical studies have been undertaken to evaluate the role of ABMT in relapse, in second and subsequent remission (CR greater than or equal to 2), and in first remission (CR1). The value of these high dose cytoreductive programs with ABMT is not yet known. No randomized studies have been done yet indicating t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Dicke KA,Spinolo JA

    更新日期:1989-01-01 00:00:00

  • Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.

    abstract::A monoclonal antibody of the IgM class, reacting with the CD9 (p24) antigen is described. The antibody (FMC27) is cytotoxic against cells of the common type of acute lymphoblastic leukaemia (c-ALL), giving killing at higher dilutions than an IgG antibody (FMC8) against the same antigen. FMC27 and FMC8 recognise differ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Zola H,Potter A,Neoh SH,Juttner CA,Haylock DN,Rice AM,Favaloro EJ,Kabral A,Bradstock KF

    更新日期:1987-02-01 00:00:00

  • Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.

    abstract::A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m(2) and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.267

    authors: Christopoulos P,Schmoor C,Waterhouse M,Marks R,Wäsch R,Bertz H,Finke J

    更新日期:2013-07-01 00:00:00

  • Chimerism monitoring following allogeneic hematopoietic stem cell transplantation.

    abstract::Information regarding the chimeric status of hematopoietic stem cell transplantation (HSCT) recipients is of great significance when comparing different conditioning and prophylactic therapies. In recent years, short tandem repeats/variable number tandem repeats (STRs/VNTRs) have emerged as the best tool for chimerism...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1705626

    authors: Talwar S,Khan F,Nityanand S,Agrawal S

    更新日期:2007-05-01 00:00:00

  • Gut protection by palifermin during autologous haematopoietic SCT.

    abstract::Conditioning therapy in connection with haematopoietic SCT (HSCT) induces a disruption of the intestinal barrier function facilitating the permeation of bacteria and endotoxin through the bowel wall with subsequent increased risk of septicaemia and a worsening of GVHD in the allogeneic setting. Palifermin (recombinant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.388

    authors: Johansson JE,Hasséus B,Johansson P,Eklöf C,Ohman D,Stockelberg D

    更新日期:2009-05-01 00:00:00

  • Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia.

    abstract::A 12-year-old girl with Fanconi anaemia (FA) received a bone marrow transplant from her HLA-identical brother following conditioning with cyclophosphamide (20 mg/kg), thoraco-abdominal radiation (TAI) (4 Gy) and equine anti-thymocyte globulin (ATG) (90 mg/kg). Engraftment was delayed and initially tenuous, and was fol...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701855

    authors: Mital MK,Curtis A,Spencer V,Barge D,Skinner R

    更新日期:1999-07-01 00:00:00

  • Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation.

    abstract::Ninety-eight patients with homozygous-beta thalassemia who had undergone allogeneic bone marrow transplantation (BMT) between May 1990 and March 1992 were tested for hepatitis C antibodies (anti-HCV) before and after BMT. Anti-HCV positivity was detected in 50 of the 98 patients (51%) before BMT. Seroconversion was de...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Erer B,Angelucci E,Lucarelli G,Giardini C,Baronciani D,Galimberti M,Polchi P,Amadei G,Battistini L,Paolucci S

    更新日期:1994-09-01 00:00:00

  • Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning.

    abstract::Autologous SCT (auto-SCT) introduces a reduced tolerance to chemotherapy even in patients with adequate engraftment, suggesting long-term effects of the transplantation procedure on the BM capacity. To study the hematopoietic cell compartment after auto-SCT, CD34(+) BM cells (n = 16) from patients at 6-9 months after ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.75

    authors: Woolthuis C,Agool A,Olthof S,Slart RH,Huls G,Smid WM,Schuringa JJ,Vellenga E

    更新日期:2011-01-01 00:00:00

  • Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.

    abstract::We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705503

    authors: Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

    更新日期:2006-11-01 00:00:00

  • Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant.

    abstract::The incidence of varicella-zoster-virus infection/reactivation in adult patients with Hodgkin's disease undergoing autologous bone marrow transplantation (BMT) at the University of Minnesota Hospital and Clinic was determined. Seven of 28 evaluable patients (25%) developed varicella-zoster infections in the first 150 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Christiansen NP,Haake RJ,Hurd DD

    更新日期:1991-06-01 00:00:00

  • High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.

    abstract::A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma patients. However, th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0196-3

    authors: Robinson SP,Boumendil A,Finel H,Dreger P,Sureda A,Hermine O,Montoto S

    更新日期:2018-12-01 00:00:00

  • Umbilical cord blood banking in The Netherlands.

    abstract::Cord blood banks are being developed in the United States and Europe. In The Netherlands, the EuroCord Nederland Foundation (ECN) has been established to coordinate the development of a national cord blood bank for unrelated transplants. The aim of ECN is to collect at least 5000 transplants for patients who lack an H...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Jacobs HC,Falkenburg JH

    更新日期:1998-07-01 00:00:00

  • Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor.

    abstract::We describe a healthy peripheral blood stem cell (PBSC) donor who developed a cutaneous reaction, erythema exsudativum multiforme, during the administration of granulocyte colony-stimulating factor (G-CSF) for mobilization. The cutaneous lesions were located on his hips, apart from the site of G-CSF injection. Treatme...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702501

    authors: Mori T,Sato N,Watanabe R,Okamoto S,Ikeda Y

    更新日期:2000-07-01 00:00:00

  • 'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    abstract::Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.223

    authors: Giaccone L,Mancini G,Mordini N,Gargiulo G,De Cecco V,Angelini S,Arpinati M,Baronciani D,Bozzoli V,Bramanti S,Calore E,Cavattoni IM,Cimminiello M,Colombo AA,Facchini L,Falcioni S,Faraci M,Fedele R,Guidi S,Iori AP,M

    更新日期:2018-01-01 00:00:00

  • A comparison of serological, cellular and DNA-RFLP methods for HLA matching in the selection of related bone marrow donors.

    abstract::Serological, cellular and DNA-RFLP (restriction fragment length polymorphism) methods of determining HLA compatibility between 10 leukaemic patients and potential related bone marrow donors were systematically compared. DR beta/DQ alpha/DQ beta/DNA-RFLP typing of these families gave results in agreement with those obt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Howell WM,Evans PR,Spellerberg MB,Wilson PJ,Smith JL

    更新日期:1989-01-01 00:00:00

  • T cell tolerance after bone marrow transplantation in mice.

    abstract::This article provides a brief overview of T cell tolerance induction in the thymus, using parent----F1 bone marrow (BM) chimeras as a model. Although intrathymic tolerance is controlled largely by BM-derived cells, experiments with BM chimeras suggest that thymic epithelial cells can make a major contribution to toler...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Sprent J,Kosaka H,Gao EK

    更新日期:1992-01-01 00:00:00

  • Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.

    abstract::We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705900

    authors: Wang Y,Ogawa Y,Dogru M,Kawai M,Tatematsu Y,Uchino M,Okada N,Igarashi A,Kujira A,Fujishima H,Okamoto S,Shimazaki J,Tsubota K

    更新日期:2008-02-01 00:00:00

  • Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.

    abstract::Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-fr...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1701941

    authors: Kanteti R,Miller K,McCann J,Roitman D,Morelli J,Hurley C,Berkman E,Schenkein D

    更新日期:1999-09-01 00:00:00

  • Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count.

    abstract::IL-7 is produced by stromal cells and is the major lympho- and thymopoietic cytokine. IL-7 induces proliferation and differentiation of immature thymocytes, and protects thymocytes from apoptosis by induction of bcl-2 expression. The regulation of IL-7 production is poorly characterized, although down-regulation by tr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701655

    authors: Bolotin E,Annett G,Parkman R,Weinberg K

    更新日期:1999-04-01 00:00:00

  • Process of allogeneic hematopoietic cell transplantation decision making for older adults.

    abstract::Allogeneic hematopoietic cell transplantation (alloHCT) may be the only curative option for some older adults with hematologic malignancies, and its associated risks of significant morbidity and mortality warrant a clear, informed decision-making process. As older adults have not been transplanted routinely until rece...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.241

    authors: Randall J,Keven K,Atli T,Ustun C

    更新日期:2016-05-01 00:00:00

  • Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

    abstract::Twenty-nine pediatric allogeneic bone marrow transplant (BMT) recipients, ages 2-17 years, were followed prospectively for cytomegalovirus (CMV) infection. Patients at risk received ganciclovir (GCV) prophylactically at a dose of 5 mg/kg/day i.v., 3 to 5 days per week, until day 100. Surveillance blood and urines were...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Canpolat C,Culbert S,Gardner M,Whimbey E,Tarrand J,Chan KW

    更新日期:1996-04-01 00:00:00

  • Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

    abstract::Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.234

    authors: Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

    更新日期:2016-05-01 00:00:00

  • A risk-adapted approach to acute GVHD treatment: are we there yet?

    abstract::Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.261

    authors: Holtan SG,MacMillan ML

    更新日期:2016-02-01 00:00:00

  • Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients.

    abstract::We conducted an observational study to assess the etiology, clinical features and outcomes of bloodstream infection (BSI) in 172 hematopoietic SCT (HCST) recipients. One hundred episodes of BSI in the pre-engraftment period (early onset) were compared with 89 episodes in the post-engraftment phase (late onset). More p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.37

    authors: Gudiol C,Garcia-Vidal C,Arnan M,Sánchez-Ortega I,Patiño B,Duarte R,Carratalà J

    更新日期:2014-06-01 00:00:00

  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.

    abstract::Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.217

    authors: Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

    更新日期:2011-07-01 00:00:00

  • Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

    abstract::BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with ~85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2014.84

    authors: Bhatia M,Jin Z,Baker C,Geyer MB,Radhakrishnan K,Morris E,Satwani P,George D,Garvin J,Del Toro G,Zuckerman W,Lee MT,Licursi M,Hawks R,Smilow E,Baxter-Lowe LA,Schwartz J,Cairo MS

    更新日期:2014-07-01 00:00:00

  • Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.

    abstract::Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that furth...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703950

    authors: Oyama Y,Traynor AE,Barr W,Burt RK

    更新日期:2003-08-01 00:00:00

  • Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

    abstract::Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.33

    authors: Milone G,Poidomani M,Leotta S,Avola G,Camuglia MG,Privitera A,Consoli C,Mercurio S,Romeo MA,Di Marco A,Di Mercurio S,Spadaro A,Palumbo GA,Tedeschi P

    更新日期:2012-01-01 00:00:00

  • Growth in homozygous beta-thalassemia after bone marrow transplantation.

    abstract::In 8 homozygous beta-thalassemic patients, aged between 1.9 and 18 years, that received bone marrow transplantation (BMT), a longtidinal study of growth before and after BMT and relative Height Standard Deviation Score (SDS), has been performed. In all patients, also after BMT, a progressive growth retardation has bee...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ponte G,Ferrara M,Esposito L

    更新日期:1991-01-01 00:00:00